Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 1c, Misses on Revenue; Offers FY26 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts AUPH Hot Sheet
Join SI Premium – FREE
Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q3 EPS of $0.23, $0.01 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $83.7 million versus the consensus estimate of $83.96 million.
GUIDANCE:
Aurinia Pharmaceuticals sees FY2026 revenue of $325-330 million, versus the consensus of $330.3 million.
For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Updates US Conviction List Directors' Cut
- This Swiss stock is ‘well positioned to deliver’ profitable growth: Citi
- Wysera Launches an AI Agent That Writes Marketing Content in a Company's Own Voice
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
